ABSTRACT
The research paper aims to examine the impact of digitalization and IoT technologies on the business world and the ways in which it also impacts the global economy. The paper examines that digital Human Resource Management can increase the productivity and the efficiency of both the HR professionals and the employees of the organisation. The findings of the research also reveals that through digitalisation the HR managers can build better relationships between the employee and the company, can think about the wellbeing of the employees better, and make them feel more valued and appreciated. It can also help in creating a competitive atmosphere in the workplace which can motivate the employees. The research further reveals that the active IoT technologies are increasing in the business world. The articles also analyses the advantages and disadvantages of implementing digitalisation and IoT in the workplace and there exists some requirements that need to be met for the successful implementation of the IoT technology. The research also estimates that in future companies can develop their business by adopting digitalisation. In the paper it is also mentioned that during the pandemic the global economy has decreased and to balance the condition it is important to implement digitalisation in the business world. © 2021 IEEE.
ABSTRACT
This review provides a pharmacological approach to combat Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) based on two comprehensive denominations which could be specifically intended for viral replication process by either inhibiting essential genomic viral enzymes or preventing viral entry to human cells. These denominations focused on immune therapies either to improve innate antiviral immune responses or to reduce impairment triggered by underactive inflammatory reactions. A variety of drug candidates are available which can inhibit SARS-CoV-2 infection and replication, comprising serine protease inhibitors: Transmembrane Orotease/Serine Subfamily member 2 (TMPRSS2), camostat mesylate, nafamostat mesylate, and angiotensin-converting enzyme inhibitors. This review is also concerned with identifying drugs and ongoing clinical trials with their mechanisms of action against SARS-CoV-2. Chloroquine and hydroxychloroquine, monoclonal antibody, off-label antiviral drugs, nucleotide analog remdesivir and broad-spectrum antiviral drugs also could be used as inhibitors of SARS-CoV-2. Moreover, non-steroidal anti-inflammatory drugs (NSAIDs), dexamethasone, and antiviral phytochemicals that are currently reachable, can prevent SARS-CoV-2 pandemic morbidity and mortality.